These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19433555)

  • 1. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
    Spellberg B; Andes D; Perez M; Anglim A; Bonilla H; Mathisen GE; Walsh TJ; Ibrahim AS
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3122-5. PubMed ID: 19433555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
    Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
    Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
    Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
    Porter JB; Taher AT; Cappellini MD; Vichinsky EP
    Hemoglobin; 2008; 32(6):601-7. PubMed ID: 19065340
    [No Abstract]   [Full Text] [Related]  

  • 9. Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy.
    Vill K; Müller-Felber W; Teusch V; Blaschek A; Gerstl L; Huetker S; Albert MH
    Neuromuscul Disord; 2016; 26(4-5):322-5. PubMed ID: 27068298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
    Ibrahim AS; Gebermariam T; Fu Y; Lin L; Husseiny MI; French SW; Schwartz J; Skory CD; Edwards JE; Spellberg BJ
    J Clin Invest; 2007 Sep; 117(9):2649-57. PubMed ID: 17786247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.
    Lee JW; Yoon SS; Shen ZX; Ganser A; Hsu HC; Habr D; Domokos G; Roubert B; Porter JB;
    Blood; 2010 Oct; 116(14):2448-54. PubMed ID: 20566896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Diamantidis MD; Neokleous N; Agapidou A; Vetsiou E; Manafas A; Fotiou P; Vlachaki E
    Int J Hematol; 2016 May; 103(5):537-44. PubMed ID: 26861970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(6):608-15. PubMed ID: 19065341
    [No Abstract]   [Full Text] [Related]  

  • 17. Iron chelation adherence to deferoxamine and deferasirox in thalassemia.
    Trachtenberg F; Vichinsky E; Haines D; Pakbaz Z; Mednick L; Sobota A; Kwiatkowski J; Thompson AA; Porter J; Coates T; Giardina PJ; Olivieri N; Yamashita R; Neufeld EJ;
    Am J Hematol; 2011 May; 86(5):433-6. PubMed ID: 21523808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.
    Nolte F; Angelucci E; Beris P; Macwhannell A; Selleslag D; Schumann C; Xicoy B; Almeida A; Guerci-Bresler A; Sliwa T; Muus P; Porter J; Hofmann WK
    Leuk Res; 2011 Sep; 35(9):1131-5. PubMed ID: 21737138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.